press

Press06/06/2019

EMN AT EHA SYMPOSIUM: BRINGING TOGETHER SCIENTIFIC COMMUNITY AND PHARMACEUTICAL INDUSTRY

In Amsterdam (June 13th 2019), a symposium chaired by Prof. Mario Boccadoro, Hematologist at the University of Turin, member of the European Myeloma Network and President of the Executive Committee of the EMN Research Italy Working Group, will deal with a very topical issue: the relationship between the scientific community and pharmaceutical companies – a highly relevant topic in the era of personalized medicine.

Prof. Mario Boccadoro, Hematologist at the University of Turin, President of the Executive Committee of the EMN Research Italy Working Group and member of the EMN European Myeloma Network, the leading network in the research and treatment in the myeloma field, will chair the Symposium "The value of collaborative research in hematology: bringing industry and scientific groups closer towards a common goal". The symposium will take place on Thursday 13th June 2019 at the RAI Exhibition and Convention Center in Amsterdam as part of the 24th annual EHA (European Hematology Association) conference scheduled from June 13th to 16th. The satellite symposium is promoted by HeaDS (Health Data Specialists), a Contract Research Organization (CRO), specialized in conducting clinical studies in the field of oncological hematology, and aims to analyse the complex relationship between scientific research and the pharmaceutical industry seeking new and more efficient collaborations and identifying areas for improvement.

A topical subject, for the first time dealt with an articulated approach and under different aspects. In fact, Tobias Kampfenkel of Janssen Pharmaceutical, Meletios A. Dimopoulos, member of the European Myeloma Network, Meral Beksac of the Balkan Myeloma Group and Ioannis Orfanidis, Health Data Specialists, will take part in the satellite symposium chaired by Prof. Boccadoro. In the current scenario, where personalized approaches and tailored therapies are needed to achieve high response rates to treatments, we need extremely precise and reliable data and appropriate clinical studies to analyse different drug combinations.

It is clear that a close and efficient collaboration between the scientific community and the pharmaceutical industry is fundamental and as such must be managed and regulated in all its aspects to allow significant and solid progress in the treatment of multiple myeloma and other plasma cell dyscrasias.

Press
02/16/2021
MULTIPLE MYELOMA: THE RESEARCH NEVER STOPS, WITH THE RESULTS ON VIEW AT THE SECOND CONGRESS OF THE EUROPEAN MYELOMA NETWORK

The Congress, initially scheduled for 2020 and postponed due to the pandemic, will now be a digital event. It will take place between 3 and 6 March and will connect haematologists and clinical trial experts across the continent.
The first edition, held at Turin’s Lingotto Congress Centre in April 2018, registered some 700 participants from 44 different countries.
Uniquely during this second edition, delegates will have the opportunity to interface directly with the speakers through instant chats.
The digital Congress is promoted by EMN International. It’s organized with the support of EMN Research Italy, the Italian operating branch of the EMN network, in collaboration with the ER Congressi agency.

read more >
Press
03/15/2022
THE THIRD EUROPEAN MYELOMA NETWORK CONFERENCE: WHAT IS NEW IN THE FIELD OF MULTIPLE MYELOMA

Between 6 and 9 April, the world of Multiple Myeloma research will convene for a virtual meeting involving haematologists and clinical trial experts from Europe and beyond.
This virtual congress is promoted by the European EMN network, headquartered in Rotterdam, with the support of the Italian team in Turin, and in collaboration with the ER Congressi agency.
New therapeutic approaches aimed at increasing survival and quality of life of myeloma patients will be addressed. Sponsored sessions will provide a valuable overview of the new molecules and innovative therapeutic approaches.

read more >

COOKIES DISCLAIMER

This website uses cookies to improve your browsing experience. By continuing to browse this website, you agree to our use of cookies. Read the privacy policy